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Objectives This study sought to determine the risk versus beneﬁt ratio of an early aggressive (EA)
approach in elderly patients with non–ST-segment elevation acute coronary syndromes (NSTEACS).
Background Elderly patients have been scarcely represented in trials comparing treatment strate-
gies in NSTEACS.
Methods A total of 313 patients 75 years of age (mean 82 years) with NSTEACS within 48 h from
qualifying symptoms were randomly allocated to an EA strategy (coronary angiography and, when indi-
cated, revascularization within 72 h) or an initially conservative (IC) strategy (angiography and revascularization
only for recurrent ischemia). The primary endpoint was the composite of death, myocardial infarction, dis-
abling stroke, and repeat hospital stay for cardiovascular causes or severe bleeding within 1 year.
Results During admission, 88% of the patients in the EA group underwent angiography (55% revascu-
larization), compared with 29% (23% revascularization) in the IC group. The primary outcome occurred in
43 patients (27.9%) in the EA group and 55 (34.6%) in the IC group (hazard ratio [HR]: 0.80; 95% conﬁ-
dence interval [CI]: 0.53 to 1.19; p  0.26). The rates of mortality (HR: 0.87; 95% CI: 0.49 to 1.56), myocar-
dial infarction (HR: 0.67; 95% CI: 0.33 to 1.36), and repeat hospital stay (HR: 0.81; 95% CI: 0.45 to 1.46) did
not differ between groups. The primary endpoint was signiﬁcantly reduced in patients with elevated tro-
ponin on admission (HR: 0.43; 95% CI: 0.23 to 0.80), but not in those with normal troponin (HR: 1.67;
95% CI: 0.75 to 3.70; p for interaction  0.03).
Conclusions The present study does not allow a deﬁnite conclusion about the beneﬁt of an EA ap-
proach when applied systematically among elderly patients with NSTEACS. The ﬁnding of a signiﬁ-
cant interaction for the treatment effect according to troponin status at baseline should be con-
ﬁrmed in a larger size trial. (Italian Elderly ACS Study; NCT00510185) (J Am Coll Cardiol Intv 2012;5:
906–16) © 2012 by the American College of Cardiology Foundation
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907Non–ST-segment elevation acute coronary syndromes
(NSTEACS) are the most common presentation of acute
ischemic heart disease in elderly individuals (1–6). How-
ever, only a minority of the patients enrolled in clinical trials
of treatment strategies in NSTEACS were 75 years old
(7). Guidelines for ACS (8,9) and percutaneous coronary
intervention (PCI) (10,11) do not discriminate elderly
See page 917
individuals as a separate category but suggest that, when
early angiography would be clinically indicated, the possible
benefit of early revascularization—suggested by subgroup
analyses of existing trials (12,13)—should be balanced with
the higher risk of procedural complications typical of elderly
individuals. The Italian Elderly ACS study is the first
randomized trial comparing an early aggressive (EA) ap-
proach with an initially conservative (IC) approach in
elderly patients with NSTEACS.
Methods
The study design has been published previously (14). The
study involved 21 centers with capability of PCI and
coronary artery bypass grafting (CABG) and 2 centers
without such capability. The study was approved by the
ethics committees of the participating hospitals. Eligible
were patients with NSTEACS and an age of75 years, with
ardiac ischemic symptoms at rest within 48 h before random-
zation, together with ischemic electrocardiographic (ECG)
hanges and/or elevated levels of either troponin or creatine
inase-myocardial band (CK-MB). Excluded were patients
ith secondary causes of myocardial ischemia, ongoing
yocardial ischemia or heart failure despite optimized
herapy, PCI or CABG within 30 days before randomiza-
ion, serum creatinine 2.5 mg/dl, a cerebrovascular acci-
ent within the previous month, recent transfusions, gas-
rointestinal or genitourinary bleeding within 6 weeks
efore randomization, platelet count 90,000 cells/l, on-
oing oral anticoagulation, severe obstructive lung disease,
alignancy, or neurological deficit limiting follow-up. All
atients meeting the inclusion criteria but with 1 of the
xclusion criteria were to be included in a dedicated registry.
ignature of the informed consent form was a prerequisite
or enrollment either in the trial or in the registry. All
atients were registered in the study by accessing a dedi-
ated website. For patients logged in the trial file, the
of Brescia, Brescia, Italy; ***Mediolanum Cardio Research, Milano, Italy; and the
†††Ospedale Civile, Legnano, Italy. Nycomed Italia and GlaxoSmithKline Italia
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M
areatment strategy was released immediately by a computer-
enerated list. Patients enrolled in the trial were randomly
ssigned to either: 1) an EA strategy of coronary angiogra-
hy within 72 h and, when indicated, coronary revascular-
zation by either PCI or CABG according to coronary
natomy, patient preference, and local skills; or 2) IC
herapy, in which case patients had to be managed with
edical therapy, and coronary angiography during index
ospital stay was allowed in the case of refractory ischemia,
yocardial (re)infarction, heart failure of ischemic origin, or
alignant ventricular arrhythmias. After discharge, coro-
ary angiography was to be considered in the case of further
dmission for an ACS or recurrent ischemic symptoms. The
tudy protocol included detailed recommendations for an-
ithrombotic therapy (14) following the guidelines for
STEACS and PCI published
t the time of study planning
8,9), adjusted for an elderly
opulation (7). Use of any other
reatment was left according to
ospital routine. Follow-up vis-
ts were planned at 30 days, 6
onths, and 12 months post-
andomization.
Outcome measures. An inde-
endent event adjudication
ommittee adjudicated all seri-
us adverse events on the basis
f the review of the original
ource documents. All surviving
atients were followed up to 1
ear, even if they had reached an
ndpoint. The primary endpoint
as the composite of all-cause
ortality, nonfatal myocardial
nfarction (MI), disabling stroke,
nd repeat hospital stay for car-
iovascular causes or severe
leeding within 12 months.
eath was classified as cardiovascular or noncardiovascular.
ardiovascular death was defined as sudden death, death
ue to MI, stroke, pulmonary embolism, procedure-related
eath, as well as unwitnessed death. Noncardiovascular
eath includes all other causes. All definite MIs were
ounted as events, whether they represented the reason for
ny hospital stay occurring after the index event or occurred
uring hospital stay. To meet the criteria as an endpoint, an
ith Proctor Medtronic. All other authors have reported that they have no
elationships relevant to the contents of this paper to disclose. From the data
resented at the 2011 Congress of the European Society of Cardiology, Paris,
rance, August 30, 2011.
anuscript received March 9, 2012; revised manuscript received May 29, 2012,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
EA  early aggressive
ECG  electrocardiogram/
electrocardiographic
HR  hazard ratio
IC  initially conservative
IQR  interquartile range
MI  myocardial infarction
NSTEACS  non–ST-segment
elevation acute coronary
syndrome(s)
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctionccepted June 7, 2012.
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908MI had to be distinct from the qualifying event. The ECG
evidence of MI required new Q waves (0.04 s) in 2 or
more contiguous leads. Cardiac marker evidence of MI
required troponin or CK-MB elevations normal limit
(15). In subjects with acute MI as the index event, within
the first 72 h after the index MI, enzyme criteria for
recurrent MI were re-elevation of CK-MB normal limit
and increased by at least 50% over the previous value.
Criteria for post-procedural MI adjudication have been
previously reported (14). Stroke was defined as any new
neurological deficit lasting 24 h. Computerized tomogra-
phy or magnetic resonance imaging was required to confirm
the stroke and to distinguish between ischemic and hemor-
rhagic stroke. Nonfatal strokes were to be counted in the
Assess
signed
Analyzed  (n= 154)
Lost to follow-up (n= 2) 
Withdrawn consent (n= 1) 
Allocated to early aggressive (n=154) 
Angiography during index admission (n=136),  
No angiography during index admission (n= 18)
Randomized (n=3
Figure 1. Study Flow Chart
Patients not enrolled in the trial for any reason were followed up for 1 year in a d
bypass graft surgery; COPD  chronic obstructive pulmonary disease; INR  internationprimary endpoint of the study and further classified as
disabling and nondisabling (14). Hospital stay due to
cardiovascular causes included severe recurrent ischemia,
coronary revascularization due to severe recurrent ischemia,
or an ACS resulting in the need for an unplanned PCI or
CABG, noncerebral systemic embolism, heart failure, car-
diac arrhythmia, and syncope. Only severe bleedings leading
to repeat hospital stay after discharge from the index event
were considered among the components of the primary
endpoint. Because the commonly used definitions of bleed-
ing endpoints in ACS patients are not suitable for events
occurring during long-term treatment (16), the event adju-
dication committee adjudicated “severe bleeding” as the
main cause for repeat hospital stay on the basis of the
eligibility after 
nt (n= 645) 
Excluded  (n=332)
ondary causes of acute myocardial ischemia (n=20) 
oing myocardial ischemia despite maximal therapy (n=47) 
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ed registry. Analysis was according to intention-to-treat. CABG  coronary arteryed for 
 conse
Sec
Ong
Ong
PCI 
Seru
Activ
Kno
Cere
Ong
Sev
Part
Inab
Othe
13) 
edicat
al normalized ratio; PCI  percutaneous coronary intervention.
c
i
b
C
R
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 9 , 2 0 1 2 Savonitto et al.
S E P T E M B E R 2 0 1 2 : 9 0 6 – 1 6 Italian Elderly ACS Study
909hemoglobin/hematocrit levels at the time of repeat hospital
stay as well as on hospital discharge summaries and narrative
summaries of the investigator. After the publication of the
Bleeding Academic Research Consortium definitions (17),
we have included in the primary endpoint the type 2, 3a,
and 3b events. Thrombolysis In Myocardial Infarction
(TIMI) major bleeding occurring during the index hospital
stay, and major bleedings after bypass surgery were counted
but not included in the primary endpoint.
Statistical analysis. In the lack of observational data on the
1-year outcome of elderly patients with NSTEACS, we extrap-
olated our estimates from the subgroup analysis of the
TACTICS (Treat Angina With Aggrastat and Determine
the Cost of Therapy With Invasive or Conservative Strat-
egy) trial (13), by adapting their 6-month event rates (death,
MI, or repeat hospital stay for ACS) to our more compre-
hensive composite endpoint. The sample size of 313 pa-
tients was based on an anticipated reduction in event rate at
12 months from 40% in the IC arm to 25% in the EA arm
of the study, with an estimated power of 80% and a 2-sided
alpha level of 0.05. The initial sample size of 504 patients,
with the primary endpoint set at 6 months and an antici-
pated reduction in event rate from 30% to 20% (14), was
amended on October 20, 2008, because of slower-than-
expected enrollment. No interim analyses were performed.
Continuous variables were compared between randomized
groups with the Wilcoxon rank sum test, whereas for binary
variables the Fisher exact test was used. Estimation of the
cumulative primary event rate was done with the Kaplan-
Meier method on an intention-to-treat basis, and events
over time were compared with the log-rank test. The Cox
proportional hazards model was used to estimate the treat-
ment effect as unadjusted hazard ratio with 95% confidence
intervals. A 2-sided p value 0.05 was considered signifi-
ant. Subgroup analyses were limited to 4 clinically mean-
ngful pre-randomization variables. Statistical analyses have
een carried out with SAS (version 9.2, SAS, Cary, North
arolina).
esults
Between January 2008 and May 2010, 645 patients signed
the consent form. Of these, 313 were enrolled in the trial,
and 332 were enrolled in the registry. Patients allocated to
the registry had a mean age of 82.5  5 years, and the
reasons for exclusion are shown in Figure 1. The baseline
characteristics of the patients enrolled in the trial are shown
in Table 1 and are well balanced. The median time from the
qualifying symptoms to randomization was 24 h (interquar-
tile range [IQR]: 11 to 36 h) and was similar in the 2 arms.
At randomization, 73% of the patients were receiving
aspirin, 6% were receiving ticlopidine, 40% were receiving
clopidogrel, 8% were receiving unfractionated heparin, 28%were receiving enoxaparin, and 4% were receiving oral
anticoagulants, without differences between groups.
During admission, 136 (88.3%) of the patients random-
ized to the EA strategy and 46 (28.9%) of those randomized
to the IC strategy underwent cardiac catheterization, at a
median of 24 h (IQR: 15 to 46 h) and 67 h (IQR: 24 to
113 h), respectively, from randomization. The reasons for
not performing coronary angiography among the EA pa-
tients were heart failure in 6 cases, withdrawn consent in 5,
bleeding in 2, sepsis in 2, and death, transient ischemic
attack, and acute renal insufficiency in 1 case each. The
indications for catheterization in the IC arm were recurrent
ischemia in 36 cases, heart failure in 6, (re)infarction in 1,
and sustained ventricular tachycardia in 2. The cardiac
revascularization procedures during admission are shown in
Table 2, and the technical details are shown in Table 3. In
the EA group, 85 patients underwent revascularization
(55% of those randomized, 62% of those who underwent
angiography), including 76 PCIs and 9 CABG. In the IC
group, 36 patients (23% of those randomized, 78% of those
Table 1. Baseline Characteristics at Randomization
EA
(n  154)
IC
(n  159) p Value
Age (yrs) 81.8 4.4 81.8 4.7 0.92
Male 76 (49) 81 (51) 0.78
Weight (kg) 72 12 72 11 0.87
Hypertension 136 (92) 123 (85) 0.03
Hypercholesterolemia 65 (44) 72 (50) 0.21
Diabetes 55 (38) 59 (41) 0.54
Previous stroke 11 (7.5) 14 (9.7) 0.26
Mean eGFR (ml/min/1.73 m2) 51 18 57 45 0.16
eGFR 50 (ml/min/1.73 m2) 69 (46) 73 (47) 0.97
Moderate mitral valve insufﬁciency 31 (20) 39 (25) 0.67
Prior myocardial infarction 43 (28) 54 (34) 0.51
Prior heart failure 16 (10) 14 (8.9) 0.55
Prior CABG 17 (11) 12 (7.6) 0.22
Prior PCI 16 (11) 31 (20) 0.08
Chronic angina 38 (25) 28 (18) 0.2
Serum hemoglobin (g/dl) 13.21 1.79 13.13 1.67 0.66
Ejection fraction (%) 49 9.7 48 10.6 0.63
Mean TIMI risk score 4.3 1.1 4.3 1.2 0.61
4 39 25 40 25 0.97
4 115 75 119 75
Atrial ﬁbrillation 23 (15) 19 (12) 0.37
Ischemic ECG changes 92 (61) 106 (67) 0.4
Elevated troponin levels 95 (64) 95 (61) 0.6
Both ischemic ECG and high markers 56 (37) 61 (39) 0.79
Values are mean SD or n (%). Categorical variables are expressed as frequencies (percentages)
and differences tested with the Fisher exact test. Continuous variables are expressed as mean
SD and differences tested with the t test.
CABG coronary artery bypass grafting; EA early aggressive; ECG electrocardiogram;
eGFR  estimated glomerular filtration rate; IC  initially conservative; PCI  percutaneous
coronary intervention; TIMI Thrombolysis In Myocardial Infarction.undergoing angiography) underwent PCI, and 1 underwent
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910CABG. None of the patients undergoing CABG died
during index hospital stay. The antithrombotic medications
during index hospital stay and at discharge are shown in
Table 4. Other medications at discharge were similar in the
2 groups, with 92% of the patients taking aspirin, 60%
Table 2. Cardiac Procedures During Initial Hospital Stay and
Within 1 Year, According to Study Group
Initial Hospital Stay Within 1 Year
Procedure
EA
(n  154)
IC
(n  159)
EA
(n  154)
IC
(n  159)
Catheterization 136 (88) 46 (29)
PCI 76 (50) 35 (23) 79 (51) 46 (29)
CABG 9 (5.8) 1 (0.6) 11 (7) 4 (2.5)
Any revascularization 85 (56) 36 (23) 90 (58) 50 (31)
Values are n (%).
Abbreviations as in Table 1.
Table 3. Details of Angiography and Revascularization Procedures
During Index Admission
EA
(n  154)
IC
(n  159)
Coronary angiography
Performed 136 (88) 46 (29)
Time from randomization (h) 24 (15–46) 67 (24–113)
Treatment
PCI immediate 65 (48) 32 (71)
PCI delayed * 13 (9.6) 4 (8.9)
Vascular access
Radial 55 (71†) 28 (78†)
Treated vessel
Left main coronary artery 5 (6.6) 3 (8.6)
Left anterior descending artery 43 (56) 22 (63)
Circumﬂex artery 27 (36) 9 (26)
Right coronary artery 29 (38) 12 (34)
Graft 5 (6.6) 1 (2.9)
Stent type 73 (96) 34 (97)
Only BMS 35 (46) 15 (43)
Only DES 35 (46) 18 (51)
BMS  DES 3 (3.9) 1 (2.9)
Procedural success‡ 74 (97) 35 (100)
Angiographic indication to CABG 19 (14) 3 (6.7)
CABG performed 9 (5.8) 1 (0.6)
1 arterial graft 9 (100) 1 (100)
Aortic valve replacement 1 0
Surgical success§ 9 (100) 1 (100)
Values are n (%) ormedian (interquartile range). *2 patients in the EA group and 1 in the IC group
underwent 2 PCI procedures during index admission. †Percentage of PCI procedures. ‡Success
after PCI as seen on angiography was defined as technical success (normal coronary artery flow
and 50% stenosis in the luminal diameter after balloon angioplasty and 20% after stent
implantation, as assessed by visual estimation of the angiograms before and after the procedure)
without the occurrence of in-hospital myocardial infarction, emergency CABG, or death. §Surgi-
cal success was defined by the surgeon as technical success without post-procedural myocardial
infarction or in-hospital death.BMS bare-metal stent(s); DES drug-eluting stent(s); other abbreviations as in Table 1.taking beta-blockers, 80% taking angiotensin-converting
enzyme inhibitors, and 80% taking statins.
The adverse clinical events during index admission are
shown in Table 5. Patients in the EA arm had slightly more
cases of death and heart failure, whereas those in the IC arm
had significantly more cases of severe recurrent ischemia.
There was only 1 case of TIMI major bleeding during
admission in the IC arm. The median length of hospital stay
was 7 days (IQR: 4 to 10 days) in the EA arm and 7 days
(IQR: 5 to 9 days) in the IC arm. Of the patients surviving
to hospital discharge, 95% were sent home, 3.3% were sent
to cardiac rehabilitation, and 1.5% were sent to a hospice,
equally distributed between groups.
Table 4. Antithrombotic Treatments During Index Hospital Stay
and at Discharge
EA
(n  154)
IC
(n  159) p Value
During hospital stay
Aspirin 146 (95) 154 (99) 0.14
Ticlopidine 7 (4.6) 3 (1.9) 0.34
Clopidogrel 138 (90) 145 (92) 0.68
GP IIb/IIIa inhibitors 26 (17) 9 (6) 0.005
GP IIb/IIIa inhibitors in PCI
patients
18 (24*) 6 (17*) 0.44
Unfractionated heparin 39 (25) 37 (24) 0.13
Enoxaparin 96 (64) 91 (59) 0.64
Bivalirudin 6 (3.8) 2 (1.3) 0.57
Fondaparinux 11 (8.5) 11 (8.5) 0.82
At discharge (n  146) (n  154)
Aspirin 135 (92) 149 (97) 0.17
Ticlopidine 4 (2.7) 3 (1.9) 0.37
Clopidogrel 106 (73) 132 (86) 0.01
Values are n (%). Binary variables were compared with Fisher exact test. *Percentage value
referred to number of patients undergoing PCI.
GP glycoprotein; other abbreviations as in Table 1.
Table 5. Adverse Clinical Events During Index Hospital Stay
Adverse Clinical Event
EA
(n  154)
IC
(n  159) p Value
Death 8 (5.2) 5 (3.1) 0.36
Myocardial infarction 3 (1.9) 5 (3.1) 0.50
Post-procedural 3 (1.9) 4 (2.5)
Severe recurrent ischemia 1 (0.6) 15 (9.4) 0.0004
Heart failure 11 (7.1) 4 (2.5) 0.06
Cardiac arrhythmia 3 (1.9) 3 (1.9) 0.97
TIMI major bleeding 0 1 (0.6) 0.27
CABG-related bleeding/transfusion 4 (2.6) 0 0.11
Non-CNS systemic embolism 1 (0.6) 0 0.30
Infection/sepsis* 2 (1.3) 1 (0.6) 0.51
Values are n (%). Adjudicated events: these do not necessarily coincidewith the events leading to
urgent angiography in the IC arm (Fig. 1), which was left to the discretion of the treating
physician. Binary variables were compared with Fisher exact test. *Nonadjudicated.CNS central nervous system; other abbreviations as in Table 1.
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911Follow-up. The primary endpoint occurred in 43 (27.9%)
patients in the EA group and 55 (34.6%) patients in the IC
group (hazard ratio: 0.80; 95% confidence interval: 0.53 to
1.19; log rank p  0.26) (Table 6). No significant differ-
nces between groups were observed for each of the primary
ndpoint components. The Kaplan-Meier curves for the
rimary endpoint and its components are shown in Figure 2.
here was no significant heterogeneity of treatment effect
ith regard to the primary outcome in subgroups stratified
ccording to age, sex, and baseline ischemic ECG changes
Fig. 3). However, statistically significant heterogeneity in
reatment effect was observed with regard to troponin levels
t trial entry: although patients with normal troponin levels
n admission had no benefit from an EA approach, those
ith elevated troponin had a significant 57% reduction in
he primary endpoint rate (p for interaction  0.0375). As
hown in Figure 4, patients with elevated troponin level on
dmission had higher rates of death and MI at 1 year
ompared with those with normal troponin level but similar
ates of repeat hospital stay.
iscussion
In the first randomized trial comparing treatment strategies
in elderly patients with NSTEACS, we enrolled patients for
whom there was no indication for emergency angiography
(8,9) or the need for medical stabilization and re-evaluation
(such as those with secondary causes of acute ischemia or
severe renal failure). In this scenario, patients with IC
Table 6. Cumulative Rates of Composite Primary End
After Randomization
Outcome
EA
(n  154)
Primary composite endpoint 43 (27.9%)
Death 19 (12.3)
Cardiovascular 16 (10.4)
Noncardiovascular 3 (2.0)
Unknown —
Myocardial infarction 11 (7.1)
Death  myocardial infarction 28 (18.2)
Disabling stroke 0
Repeat hospital stays for
CV causes or severe bleeding 18 (11.7)
Cardiovascular causes 16 (10.4)
Severe recurrent ischemia 0
Revascularization 5 (3.3)
Heart failure 7 (4.6)
Non-CNS embolism 0
Cardiac arrhythmia 4 (2.6)
Severe bleeding* 2 (1.3)
Noncardiovascular causes 8 (5.2)
Values are n (%). *Bleeding Academic Research Consortium grades 2, 3CI confidence interval; CV cardiovascular; HR hazard ratio; other abbtreatment experienced significantly more ischemic events
during index admission, although these were mostly epi-
sodes of recurrent ischemia prompting urgent angiography.
Within 1 year, we observed a 20% difference in the rates of
our primary endpoint between the EA and the IC cohorts.
This difference was not statistically significant in the present
trial, which was powered for a 40% difference in the primary
endpoint rate. However, patients with elevated troponin
levels on admission randomized to an EA approach had a
significant 57% reduction of the primary endpoint rate:
albeit with the methodological limitation of a subgroup
finding in a negative trial, this observation is clinically sound
and in line with prior studies in the general population of
NSTEACS patients. Just recently, Damman et al. (18) have
ublished the long-term follow-up of the FIR (FRISC II–
CTUS–RITA 3) trials comparing routine invasive or
elective invasive strategy in NSTEACS, also showing the
esults in patients of 75 years of age. Although the cohort
75 years had a mean age of just 76 years (compared with
2 years in our study), a 29% reduction in cardiovascular
eath or MI at 5 years was achieved by a routine invasive
pproach in elderly patients.
Almost as predicted by our working hypothesis, 35% of
he patients in the IC arm reached the primary endpoint
ithin 1 year, although in this patient population, we had
ypothesized higher rates of urgent repeat hospital stays.
he low rate of recurrent admissions in the present study is
emarkable, especially when compared with the TIME
and Its Components Within 1 Year
IC
159) HR (95% CI) Log-Rank p Value
4.6%) 0.80 (0.53–1.19) 0.26
3.8) 0.87 (0.49–1.56) 0.65
0.7)
.5)
.6)
0.7) 0.67 (0.33–1.36) 0.27
1.4) 0.85 (0.52–1.41) 0.53
3.8) 0.81 (0.45–1.46) 0.49
3.2)
.5)
.7)
.5)
.6)
.9)
.6)
.3)
3b.point
(n 
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a, andreviations as in Tables 1 and 5.
y. CI 
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912(Trial of Invasive Versus Medical Therapy in Elderly
Patients) trial of elderly patients with stable angina, which
reported a 72% rate of hospital readmission for ACS at 12
months in the conservative group (19). Our repeat hospital
stay rates were even lower than those reported in the
ICTUS (Invasive versus Conservative Treatment in Unsta-
ble coronary Syndromes) trial, which had an average age of
62 years (20). These differences are likely attributable to the
strict adjudication criteria used in our study to define
hospital stays due to severe recurrent ischemia or a new
ACS episode (14).
By contrast, the observed mortality rate of 14% in our
conservative arm was almost twice as high as that reported
at 6 months in patients 75 years in the TACTICS trial
(13), but the difference in favor of the EA arm was marginal.
Meta-analyses of earlier trials comparing treatment strate-
gies in the general population of NSTEACS (21,22) show
an excess in mortality in the invasive arm during index
admission followed by a higher mortality in the conservative
Figure 2. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves (A) for the primary outcome (death, myocardial in
bleeding), (B) for all-cause mortality, (C) for MI, and (D) for repeat hospital staarm at follow-up. However, none of the 3 larger trialsshowed any difference in mortality within 1 year (23–25),
and in the TIME trial, mortality at 12 months was
numerically higher in the revascularization arm (19).
The rates of recurrent MI observed in our study are
similar to those observed in the ICTUS trial (20) at 1
year and in TACTICS at 6 months (13). There were
numerically more MIs during the index hospital stay in
the IC arm, and this difference was maintained at 1 year
without any significant additional risk compared with the
EA arm.
Both during the initial hospital course and during follow-
up, the rates of major bleeding were surprisingly low, with
only 2 cases occurring in the EA arm, and 2 occurring in the
IC arm. The in-hospital TIMI major bleeding rate was
dramatically lower, compared with that observed in patients
75 years in the TACTICS study, which reported 16.5% in
the EA arm versus 6.5% in the IC arm (13). This might be
explained by the much lower use of glycoprotein IIb/IIIa
antagonists in our study and because 70% of the PCI
on [MI], disabling stroke, and repeat hospital stay for cardiovascular causes or
conﬁdence interval; HR  hazard ratio.farctiprocedures were by the radial approach. At follow-up,
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913hospital admissions due to severe bleeding were also ex-
tremely rare compared with published trials and registries
(26,27).
Compared with other contemporary trials (13,20), the
present study had a lower “crossover” rate from conservative
treatment to revascularization. The moderate difference in
revascularization rates between groups might be considered
among the reasons for the nonsignificant difference in
outcome between the EA and the IC strategy in the
present study. However, although in other trials this
finding was due to the high rate of revascularization in
the conservative arm (20), in our study, only 30% of the
patients underwent revascularization in the conservative
arm, as compared with 60% in the aggressive arm,
possibly because of the extensive coronary disease of the
elderly population and the reluctance to perform CABG
in the cases nonsuitable for PCI.
As in previous trials (22), the effect of an EA approach
was larger in patients at higher risk, such as men, those with
age above median, those with ischemic ECG changes, and
especially in those with elevated troponin levels on admis-
sion. We observed a trend toward harm only in patients
with normal troponin levels on admission. Most likely, after
Figure 3. Cumulative Primary Event Rate in Subgroups
Chart shows the hazard ratios (HRs) and 95% conﬁdence intervals (CIs). Nomin
(EA) approach was higher in the higher-risk groups, and a statistically signiﬁca
trial entry. ECG  electrocardiogram.exclusion of patients with severe renal dysfunction, theelevation in cardiac troponin levels is highly specific for the
diagnosis of an ACS and thus indicates which patients
might derive benefit from an approach specifically directed
toward improving coronary circulation or acute thrombosis.
Similar to our results, in the ISAR–REACT (Intracoronary
Stenting and Antithrombotic Regimen–Rapid Early Action
for Coronary Treatment) 2 trial, elevated troponin levels at
admission were the discriminator factor between benefit and
no effect of abciximab among NSTEACS patients under-
going PCI (28). However, the results of the ICTUS
trial—showing no benefit from an intended early invasive
strategy but only from actual revascularization, among
NSTEACS troponin-positive patients (29)—leave some
uncertainty about the value of elevated troponin as the
single determinant of treatment strategy.
The main limitation of our study is its relative lack of
power, because our original sample size was amended due to
slow enrollment, and we might have been too optimistic in
anticipating a possible 37.5% reduction in our primary
endpoint in the EA arm of the study. As a matter of fact,
such a large benefit was observed only in the higher-risk
patients (such as the oldest male patients and those with
clearly ischemic ECG changes) and achieved statistical
alues for interaction are given. The relative beneﬁt of an early aggressive
raction for treatment effect was observed according to troponin status atal p v
nt intesignificance in patients with elevated troponin levels at study
n Figu
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914entry. A larger study would be needed to prospectively
confirm these data. However, consistent trends toward the
reduction in all the components of our primary endpoints
were observed, and the overall relative reduction in the
primary endpoint rate is consistent with those of earlier
meta-analyses comparing treatment strategies in NSTEACS
(21,22).
Slow enrollment and lower-than-projected sample size is
a common feature of a number of trials comparing treat-
ment strategies in high-risk patients (30–33), particularly in
the elderly population (34). This problem derives from
multiple causes, including the difficulty of obtaining in-
formed consent in elderly patients, the presence of numer-
ous comorbidities, and in the specific case, that most
cardiologists prefer an EA approach irrespective of patient
age. Finally, not all the patients randomized to the EA
approach actually underwent angiography, and only 56%
underwent revascularization, during index admission. How-
ever, these figures are not far from those of the FIR
collaboration (18), which reported a 65% revascularization
rate during index admission in their elderly cohort—which,
Figure 4. 1-Year Rates of Primary Endpoint and Its Components According
1-year rates of the primary endpoint and its components according to treatme
entry. In patients with elevated troponin levels, all the components of the prim
troponin-negative patients. IC  initially conservative; other abbreviations as ihowever, was 6 years younger than ours.Conclusions
Due to its limited power, the present study does not allow
a definite conclusion about the benefit of an EA approach
when applied systematically among elderly patients with
NSTEACS. The finding of a significant interaction for the
treatment effect according to troponin status at baseline,
with benefit confined in troponin-positive patients, should
be confirmed in a larger size trial.
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